Regeneron Pharmaceuticals Inc
REGN575.060USD
+2.470+0.43%
Fechamento 09/16, 16:00（ET）Cotações atrasadas em 15 min
61.19BValor de mercado
13.72P/L TTM
Mais detalhes de Regeneron Pharmaceuticals Inc Empresa
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Informações da empresa
Código da empresaREGN
Nome da EmpresaRegeneron Pharmaceuticals Inc
Data de listagemApr 02, 1991
CEODr. Leonard S. Schleifer, M.D., Ph.D
Número de funcionários15106
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 02
Endereço777 Old Saw Mill River Road
CidadeTARRYTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10591
Telefone17813705000
Sitehttps://www.regeneron.com/
Código da empresaREGN
Data de listagemApr 02, 1991
CEODr. Leonard S. Schleifer, M.D., Ph.D
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
19.75K
+20.78%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.37K
+9.94%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Sanofi
1.18B
39.07%
EYLEA
736.00M
24.30%
Bayer
343.90M
11.35%
EYLEA HD
306.80M
10.13%
Libtayo
192.50M
6.36%
Outro
266.30M
8.79%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Sanofi
1.18B
39.07%
EYLEA
736.00M
24.30%
Bayer
343.90M
11.35%
EYLEA HD
306.80M
10.13%
Libtayo
192.50M
6.36%
Outro
266.30M
8.79%
Distribuição de ações
Atualizado em: sáb, 30 de ago
Atualizado em: sáb, 30 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.44%
State Street Global Advisors (US)
4.64%
Dodge & Cox
3.67%
Fidelity Management & Research Company LLC
3.13%
Outro
74.12%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.44%
State Street Global Advisors (US)
4.64%
Dodge & Cox
3.67%
Fidelity Management & Research Company LLC
3.13%
Outro
74.12%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.67%
Investment Advisor/Hedge Fund
28.51%
Hedge Fund
5.34%
Research Firm
2.70%
Pension Fund
2.54%
Bank and Trust
2.15%
Individual Investor
2.01%
Sovereign Wealth Fund
1.22%
Insurance Company
0.08%
Outro
7.78%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
2023Q1
2366
99.66M
92.70%
-1.10M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
9.36M
8.81%
+117.55K
+1.27%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.74M
5.41%
+45.93K
+0.81%
Mar 31, 2025
State Street Global Advisors (US)
4.79M
4.51%
-42.58K
-0.88%
Mar 31, 2025
Dodge & Cox
2.32M
2.19%
+2.77K
+0.12%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.40M
6.97%
-573.19K
-7.19%
Mar 31, 2025
Capital International Investors
3.99M
3.76%
-747.80K
-15.79%
Mar 31, 2025
JP Morgan Asset Management
4.08M
3.84%
-1.16M
-22.19%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.47M
2.33%
+41.95K
+1.73%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
2.19M
2.07%
-36.81K
-1.65%
Jun 30, 2025
Putnam Investment Management, L.L.C.
1.91M
1.8%
+285.04K
+17.50%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
Amplify Weight Loss Drug & Treatment ETF
7.43%
Simplify Health Care ETF
7.25%
Invesco Nasdaq Biotechnology ETF
6.57%
ProShares Ultra Nasdaq Biotechnology
6.13%
iShares Biotechnology ETF
5.83%
VanEck Biotech ETF
5.37%
iShares Genomics Immunology and Healthcare ETF
4.74%
First Trust NYSE Arca Biotechnology Index Fund
3.43%
First Trust NASDAQ Pharmaceuticals ETF
3.36%
iShares US Tech Breakthrough Multisector ETF
2.99%
Ver Mais
Amplify Weight Loss Drug & Treatment ETF
Proporção7.43%
Simplify Health Care ETF
Proporção7.25%
Invesco Nasdaq Biotechnology ETF
Proporção6.57%
ProShares Ultra Nasdaq Biotechnology
Proporção6.13%
iShares Biotechnology ETF
Proporção5.83%
VanEck Biotech ETF
Proporção5.37%
iShares Genomics Immunology and Healthcare ETF
Proporção4.74%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.43%
First Trust NASDAQ Pharmaceuticals ETF
Proporção3.36%
iShares US Tech Breakthrough Multisector ETF
Proporção2.99%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
